Vaccine Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
DNA Vaccines
Findings from Rockefeller University, Aaron Diamond AIDS Research Center broaden understanding of DNA vaccines
May 21st, 2008
Research findings, 'Enhancement of HIV DNA vaccine immunogenicity by the NKT cell ligand, alpha-galactosylceramide,' are discussed in a new report. "A number of studies have shown that the natural killer T cell (NKT) ligand alpha-galactosylceramide (alpha-GalCer) serves as an adjuvant for various vaccines, including viral vaccines, parasite vaccines and protein vaccines. In this report, we investigated the adjuvant activity of alpha-GalCer on HIV-1 DNA vaccines in mice," scientists in the United States report. "This is a first study to show that alpha-GalCer can enhance the immunogenicity of DNA vaccines, since co-administration of alpha-GalCer with suboptimal doses of...
Source: Vaccine Weekly (2008-05-21)
|
